Online Program Home
My Program

Abstract Details

Activity Number: 490
Type: Contributed
Date/Time: Wednesday, August 3, 2016 : 8:30 AM to 10:20 AM
Sponsor: Biopharmaceutical Section
Abstract #319671
Title: Adaptive Estimation of Personalized Maximum Tolerated Doses in Cancer Phase I Clinical Trials According to All Toxicities and Individual Characteristics
Author(s): Zhengjia Chen* and Zheng Li and Ying Yuan and Michael Kutner and Taofeek Owonikoko and Walter J. Curran and Jeanne Kowalski
Companies: Emory University and Penn State University and MD Anderson Cancer Center and Emory University and Emory University and Emory University and Emory University
Keywords: Phase I Clinical Trial ; Biomarkers ; Covariates ; Personalized MTD ; EWOC-NETS

Many biomarkers have recently been found to play a significant role in cancer therapy. Estimation of personalized maximum tolerated doses (pMTDs) is a critical step toward personalized medicine, which aims to maximize the therapeutic effect of a treatment for individual patients. In this manuscript, we propose to further utilize patient biomarkers that can predict susceptibility to specific adverse events and response as covariates to estimate pMTDs based on a cutting-edge cancer Phase I clinical trial design called escalation with overdose control using normalized equivalent toxicity score (EWOC-NETS), which fully utilizes all toxicities. The methodology of incorporating patient biomarker information in the estimation of pMTDs for novel cancer therapeutic agents is fully elaborated and the design operating characteristics are evaluated with extensive simulations. Simulation studies demonstrate that utilization of biomarkers in EWOC-NETS can estimate pMTDs while maintaining its original merits, such as ethical constraint of overdose control and full utilization of all toxicity information, to improve the accuracy and efficiency of the pMTD estimation.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2016 program

Copyright © American Statistical Association